Patient Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (Valsartan/Sacubitril) in Heart Failure (PROVIDE-HF)

PI(s): Robert Mentz, Duke University

Project Summary: This study investigated the change in patient-reported heart failure symptoms (using the Kansas City Cardiomyopathy Questionnaire) following the initiation of sacubitril/valsartan through 12 weeks.

Study Design: Prospective Study

PaTH Partners:

• Johns Hopkins University (Dan Ford and Martha Abshire, Site co-PIs)
• University of Pittsburgh / UPMC (Marc Simon, Site PI)

Coordinating Center: Duke University